Physician profile
Thuan Vu
NPI 1366407918
$12,485.42
in general payments reported to CMS, 2019-2025
36 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,085 · 2020: $1,488 · 2021: $1,270 · 2022: $1,890 · 2023: $2,185 · 2024: $1,465 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,730 · Education: $23.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,730.01 |
| Education | $23.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,136.69 | 2019-2025 | Enbrel, Evenity, Otezla |
| Abbvie INC. | $1,738.06 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Pfizer INC. | $1,282.58 | 2019-2025 | |
| Celgene Corporation | $1,224.53 | 2019 | |
| Ucb, INC. | $1,048.14 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $672.43 | 2019-2025 | |
| Glaxosmithkline, LLC. | $545.35 | 2019-2025 | Benlysta |
| Genzyme Corporation | $482.29 | 2019-2024 | |
| Janssen Biotech, INC. | $478.96 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $441.15 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $414.78 | 2019-2022 | |
| Lilly USA, LLC | $284.58 | 2019-2024 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $259.21 | 2021-2025 | Saphnelo |
| Globus Medical, INC. | $176.46 | 2025 | Senza |
| Aurinia Pharma U.S., INC. | $173.80 | 2021-2023 | Lupkynis |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $170.87 | 2023-2025 | Idacio, Tyenne |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.21 | 2020-2025 | Cyltezo, Ofev |
| Johnson & Johnson Health Care Systems INC. | $150.00 | 2024 | Tremfya |
| Organon LLC | $131.49 | 2021-2024 | Renflexis, Hadlima |
| Genentech USA, INC. | $103.58 | 2019-2024 | Actemra |
| Bioventus LLC | $58.62 | 2019-2023 | Supartz Fx Sodium Hyaluronate |
| Hikma Pharmaceuticals USA | $52.05 | 2019 | |
| Ani Pharmaceuticals, INC. | $40.39 | 2023-2024 | Purified Cortrophin Gel |
| Tonix Medicines, INC. | $34.14 | 2025 | Tonmya |
| Sobi, INC | $28.58 | 2019 | |
| Radius Health, INC. | $27.61 | 2023 | Tymlos |
| Alexion Pharmaceuticals, INC. | $24.86 | 2024 | Strensiq |
| Celltrion USA INC. | $23.57 | 2023 | Yuflyma |
| Octapharma USA, INC. | $22.50 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.12 | 2022 | |
| Zimmer Biomet Holdings, INC. | $14.86 | 2024 | Gps III Platelet Concentration System |
| Medtronic, INC. | $14.28 | 2024 | Intellis Adaptivestim |
| Tersera Therapeutics LLC | $14.12 | 2025 | Quzyttir |
| Ferring Pharmaceuticals INC. | $12.68 | 2019 | |
| Avion Pharmaceuticals | $12.38 | 2020 | |
| Medexus Pharma, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thuan Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.